Elicio (ELTX) Q2 Loss Beats Estimates
Elicio Therapeutics (NASDAQ:ELTX), a biotechnology company focused on immunotherapies for cancer, reported its second quarter results on August 7, 2025, for the period ending June 30. The company recorded a net loss per share of $0.66 (GAAP) for the second quarter, less than the expected $(0.69) loss (GAAP). Research and development spending (GAAP) fell from the prior year, while general administration costs increased. No product revenue was reported, as the company remains in the clinical development phase. The quarter’s highlight was a positive independent review allowing its lead pancreatic cancer vaccine trial to proceed as planned. Elicio’s operating spending and cash balance reflected steady management ahead of an important upcoming clinical milestone.
Source: Analyst estimates for the quarter provided by FactSet.
Elicio Therapeutics operates as a clinical-stage biotechnology company. It develops immunotherapies to help the body’s immune system recognize and attack cancer by targeting specific genetic mutations that drive tumor growth. The company’s core technology, called Amphiphile (AMP), is engineered to direct vaccine components to the lymph nodes, which play a central role in activating immune cells known as T cells.
Source Fool.com
